

FILE 'REGISTRY' ENTERED AT 10:48:28 ON 04 DEC 2007
L8 STRUCTURE UPLOADED
L9 1 S L8
L10 29 S L8 SSS FULL

FILE 'STNGUIDE' ENTERED AT 10:49:44 ON 04 DEC 2007

FILE 'REGISTRY' ENTERED AT 10:51:50 ON 04 DEC 2007
L11 STRUCTURE UPLOADED
L12 0 S L11
L13 1 S L11 SSS FULL

FILE 'STNGUIDE' ENTERED AT 10:53:18 ON 04 DEC 2007

FILE 'REGISTRY' ENTERED AT 10:55:13 ON 04 DEC 2007
L14 STRUCTURE UPLOADED
L15 0 S L14
L16 9 S L14 SSS FULL

FILE 'STNGUIDE' ENTERED AT 10:56:14 ON 04 DEC 2007

FILE 'REGISTRY' ENTERED AT 10:57:39 ON 04 DEC 2007
L17 STRUCTURE UPLOADED
L18 0 S L17
L19 15 S L17 SSS FULL
L20 54 S L10 OR L13 OR L16 OR L19

FILE 'CAPLUS' ENTERED AT 11:00:38 ON 04 DEC 2007
L21 4 S L20

FILE 'REGISTRY' ENTERED AT 11:00:49 ON 04 DEC 2007

=>
Uploading C:\Program Files\Stnexp\Queries\test-12-4-07-14.str

L8 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\test-12-4-07-15.str



L11 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\test-12-4-07-16.str

L14 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\test-12-4-07-17.str

L17 STRUCTURE UPLOADED



chain nodes :

8 9 10 11 13 16 17 18 26 27 28 29 42 47

ring nodes :

1 2 3 4 5 6 20 21 22 23 24 25 30 31 32 33 34 35 36 37 38 39 40 41

chain bonds :

6-11 8-9 8-10 11-13 13-16 13-18 16-17 18-23 26-28 26-27 28-47 29-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 30-31 30-35
31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41

exact/norm bonds :

6-11 8-9 8-10 11-13 13-16 13-18 16-17 18-23 26-28 26-27 28-47 29-31

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 30-31 30-35
31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41

isolated ring systems :

containing 1 : 20 : 30 : 36 :

G2: [*1], [*2], [*3]

Connectivity :

18:2 E exact RC ring/chain 42:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:Atom 13:CLASS 16:CLASS 17:CLASS 18:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:Atom 31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom
42:CLASS

47:CLASS 48:Atom





Generic attributes :

18:

Saturation : Saturated

42:

Saturation : Saturated



chain nodes :

8 9 12 13 14 22 23 24 25 38 43 45 46 47 48 49

ring nodes :

1 2 3 4 5 6 16 17 18 19 20 21 26 27 28 29 30 31 32 33 34 35 36 37

chain bonds :

6-8 8-9 9-12 9-14 12-13 14-19 22-24 22-23 24-43 25-27 45-46 46-47 47-48
47-49

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 26-27 26-31
27-28 28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37

exact/norm bonds :

6-8 8-9 9-12 9-14 12-13 14-19 22-24 22-23 24-43 25-27 45-46 46-47 47-48
47-49

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 26-27 26-31
27-28 28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37

isolated ring systems :

containing 1 : 16 : 26 : 32 :

G2:[*1],[*2],[*3]

Connectivity :

14:2 E exact RC ring/chain 38:1 E exact RC ring/chain 46:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 12:CLASS 13:CLASS
14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS 23:CLASS
24:CLASS

25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS 43:CLASS 44:Atom 45:CLASS
46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:Atom

Generic attributes :

14:

Saturation : Saturated

38:

Saturation : Saturated

46:

Saturation : Saturated

8 9 10 11 13 16 17 18 20 21 22 23 36 41 42

1 2 3 4 5 6 24 25 26 27 28 29 30 31 32 33 34 35 44 45 46 47 48 49

6-11 8-9 8-10 11-13 13-16 13-18 16-17 18-42 20-22 20-21 22-41 23-25 42-47

1-2 1-6 2-3 3-4 4-5 5-6 24-25 24-29 25-26 26-27 27-28 28-29 30-31 30-35

31-32 32-33 33-34 34-35 44-45 44-49 45-46 46-47 47-48 48-49

6-11 8-9 8-10 11-13 13-16 13-18 16-17 18-42 20-22 20-21 22-41 23-25 42-47

1-2 1-6 2-3 3-4 4-5 5-6 24-25 24-29 25-26 26-27 27-28 28-29 30-31 30-35

31-32 32-33 33-34 34-35 44-45 44-49 45-46 46-47 47-48 48-49

containing 1 : 24 : 30 : 44 :

18:2 E exact RC ring/chain 36:1 E exact RC ring/chain

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:Atom 13:CLASS 16:CLASS 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
34:Atom 35:Atom 36:CLASS 41:CLASS 42:Atom 44:Atom 45:Atom 46:Atom 47:Atom
48:CLASS
```

49:Atom 50:Atom

Generic attributes :

18:

Saturation : Saturated

36:

Saturation : Saturated

42:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic





Element Count :

Node 42: Limited

C,C3

N,N1

S,S1



chain nodes :

8 9 12 13 14 16 17 18 19 32 37 38 47 48 49 50 51

ring nodes :

1 2 3 4 5 6 20 21 22 23 24 25 26 27 28 29 30 31 40 41 42 43 44 45

chain bonds :

6-8 8-9 9-12 9-14 12-13 14-38 16-18 16-17 18-37 19-21 38-43 47-48 48-49
49-50 49-51

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-31
27-28 28-29 29-30 30-31 40-41 40-45 41-42 42-43 43-44 44-45

exact/norm bonds :

6-8 8-9 9-12 9-14 12-13 14-38 16-18 16-17 18-37 19-21 38-43 47-48 48-49
49-50 49-51

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-31
27-28 28-29 29-30 30-31 40-41 40-45 41-42 42-43 43-44 44-45

isolated ring systems :

containing 1 : 20 : 26 : 40 :

G2: [*1], [*2], [*3]

Connectivity :

14:2 E exact RC ring/chain 32:1 E exact RC ring/chain 48:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 12:CLASS 13:CLASS
14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom

25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS
37:CLASS 38:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:CLASS 45:Atom 46:Atom
47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:Atom

Generic attributes :

14:
Saturation : Saturated
32:
Saturation : Saturated
38:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic
48:
Saturation : Saturated

Element Count :

Node 38: Limited
C,C3
N,N1
S,S1

```
=> s us200!-565557/apps
      2 US200!-565557/AP
      1 US200!-565557/PRN
L23    2 US200!-565557/APPS
      (US200!-565557/AP, PRN)
```

```
=> s l21 and l23
L24    1 L21 AND L23
```

```
=> d l24 bib abs
```

```
L24  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:120736  CAPLUS
DN   142:219051
TI   Preparation of aryl dicarboxamides as protein-tyrosine phosphatase
      inhibitors
IN   Thomas, Russel J.; Swinnen, Dominique; Pons, Jean-Francois; Bombrun, Agnes
PA   Applied Research Systems Ars Holding N.V., Neth.
SO   PCT Int. Appl., 103 pp.
      CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011685	A1	20050210	WO 2004-EP51558	20040720
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004260831	A1	20050210	AU 2004-260831	20040720
	CA 2529662	A1	20050210	CA 2004-2529662	20040720
	EP 1656139	A1	20060517	EP 2004-742005	20040720
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528157	T	20061214	JP 2006-520836	20040720
	US 2006189583	A1	20060824	US 2006-565557	20060123 <--
	NO 2006000815	A	20060220	NO 2006-815	20060220
PRAI	EP 2003-102236	A	20030721		
	US 2003-517824P	P	20031106		
	WO 2004-EP51558	W	20040720		
OS	CASREACT 142:219051; MARPAT 142:219051				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

```
AB   Title compds. I [A = CONHR6 wherein R6 = alkyl, alkenyl, alkynyl,
      cycloalkyl, etc.; X = aryl, heteroaryl, arylheteroaryl, arylaryl, etc.; n
      = 0 or 1; R1 and R2 independently = H or alkyl; R3 = alkyl, alkenyl,
      alkynyl, alkoxy, etc.; R4 and R5 independently = H, OH, alkyl, carboxy,
      alkoxy, etc.], and their pharmaceutically acceptable salts, are prepared and
      disclosed as protein-tyrosine phosphatase inhibitors. Thus, e.g., II was
      prepared via reductive amination of 6-amino-2,2-dimethyl-4H-1,3-benzodioxin-
```

4-one (preparation given) with 4-formylbenzoate and subsequent amidation with 3-cyclopentylpropanoyl chloride, debenzylation, amidation with 4-phenoxybenzylamine and deprotection. I were evaluated for inhibition of PTP, and in particular PTP1B; e.g., II possessed an IC50 value of 1.0 μ M in assays against PTP1B. As PTP inhibitors, I should be useful for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

GI



AB Title compds. [wherein R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl, heterocycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, (alkenyl)aryl, heteroaryl, (alkynyl)aryl, heteroaryl; R2, R3 = independently H or alkyl; Cy = aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that four compds. are excluded: their geometrical isomers, optically active forms as enantiomers, diastereomers and racemates, and pharmaceutically acceptable salts and active derivs.] were prepared as inhibitors of protein tyrosine phosphatases (PTPases), in particular PTP1B. Examples include over 400 in compds., five pharmaceutical formulations, and two biol. assays. For example, II, a 1,4-bis(4-oxo-4-phenylbut-3-en-1-yl)-2-phenylbenzoic acid with dodecylamine in THF in the presence of 4-methylmorpholine and iso-Bu chloroformate for 3 h at room temperature, reductive amination with 4-trifluoromethylbenzylamine in DCE in the presence of NaBH(OAc)3, TEA-acylation with chlorooxoacetic acid Et ester in THF, and base-catalyzed hydrolysis of the ester. II exhibited an IC50 value of 2.224 μ M for inhibition of PTP1B, 1.40 μ M for GLBP-1, 2.40 μ M for SHP-1, and 2.70 μ M for SHP-2 in an *in vitro* assay. In an *in vivo* postprandial glycemia model in db/db mice, II, at 20-200 mg/kg orally, decreased blood glucose level by 17% at 20 mg/kg, by 42% at 100 mg/kg, and by 48% at 200 mg/kg, with decreases in serum insulin levels of ~20, 68, and 89%, resp. Thus, I and their formulations are useful for the treatment and prevention of metabolic disorders such as insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

IT 575622-53-4F, 4-[[[(Carboxy)carbonyl] 3-
[(dodecylamino) carbonyl]benzyl]amino]methyl]benzoic acid
575622-21-4F, 3-[[[(Carboxy)carbonyl] 3-
[(dodecylamino) carbonyl]benzyl]amino]methyl]benzoic acid
575623-67-0F, 4-[[[(Carboxy)carbonyl] 4-
[(dodecylamino) carbonyl]benzyl]amino]methyl]benzoic acid
575622-34-2F, 3-[[[(Carboxy)carbonyl] 4-
[(dodecylamino) carbonyl]benzyl]amino]methyl]benzoic acid
RL-101C (Pharmacological use); SPN (Synthetic preparation)
(Therapeutic use); BIOL (Biological study); PREP (Preparation)
(Uses).

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064376	A1	20030807	WO 2003-EP808	20030127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, NA, MD, MG, MK, MN, MM, MX, NZ, OM, PA, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RM: CH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, OM, RO, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2472021	A1	20030807	CA 2003-2472021	20030127
EP	1470102	A1	20041027	EP 2003-734697	20030127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, BG, HK, CY, AL, BA, BR, BZ, CZ, EG, HU, SK				
BR	2003071394	A	200411-79	BR 2003-071394	20030127
JP	2005516061	A	20050602	JP 2003-564000	20030127
CN	1633410	A	20050629	CN 2003-807036	20030127
ZA	2004005179	A	20050629	ZA 2004-5179	20040629
IN	2004DN01884	A	20070406	IN 2004-DN1884	20040701
MX	2004PA07253	A	20041029	MX 2004-PA7253	20040727
NO	2004003520	A	20041005	NO 2004-1690	20040824
US	2005124656	A1	20050609	US 2005-501344	20050126
PRAT	EP 2002-100078	A	20020129		
	EP 2002-100014	A	20020129		
WO	2003-EP808	A	20030127		
QS	MRPAT 119:179889				



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```

>> log hold
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                23.60      1063.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                               ENTRY      SESSION
CA SUBSCRIBER PRICE                 -3.12      -3.12

```



=> d his

(FILE 'HOME' ENTERED AT 21:34:50 ON 03 DEC 2007)

FILE 'REGISTRY' ENTERED AT 21:35:03 ON 03 DEC 2007

L1 STRUCTURE UPLOADED
L2 991044 S NCSC2/ES
L3 0 S L1 SAM SUB=L2
L4 0 S L1
L5 4 S L1 SSS FULL SUB=L2

FILE 'CAPLUS' ENTERED AT 21:36:37 ON 03 DEC 2007

L6 1 S L5



=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.



chain nodes :

8 9 13 14 15 16 17 18 19 20 23 24 25 26 29 31 32 33 34 35 37

ring nodes :

1 2 3 4 5 6

chain bonds :

6-8 8-9 9-13 9-15 13-14 15-37 16-18 16-17 16-37 19-20 20-33 24-25 24-26
31-32 33-34 33-35

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-8 8-9 9-13 9-15 13-14 15-37 16-18 16-17 16-37 19-20 20-33 24-25 24-26
31-32 33-34 33-35

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G2:[*1],[*2],[*3],[*4]

Connectivity :

8:2 E exact RC ring/chain 15:2 E exact RC ring/chain 20:2 E exact RC ring/chain
32:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 13:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 23:CLASS 24:CLASS 25:CLASS
26:CLASS 29:CLASS 30:Atom 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 37:Atom

Generic attributes :

8:
Saturation : Saturated
37:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :

Node 37: Limited

C,C3

S,S1

N,N1

=> d 16 bib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:120736 CAPLUS
DN 142:219051
TI Preparation of aryl dicarboxamides as protein-tyrosine phosphatase inhibitors
IN Thomas, Russel J.; Swinnen, Dominique; Pons, Jean-Francois; Bombrun, Agnes
PA Applied Research Systems Ars Holding N.V., Neth.
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011685	A1	20050210	WO 2004-EP51558	20040720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260831	A1	20050210	AU 2004-260831	20040720
	CA 2529662	A1	20050210	CA 2004-2529662	20040720
	EP 1656139	A1	20060517	EP 2004-742005	20040720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528157	T	20061214	JP 2006-520836	20040720
	US 2006189583	A1	20060824	US 2006-565557	20060123
	NO 2006000815	A	20060220	NO 2006-815	20060220
PRAI	EP 2003-102236	A	20030721		
	US 2003-517824P	P	20031106		
	WO 2004-EP51558	W	20040720		
OS	CASREACT 142:219051; MARPAT 142:219051				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = CONHR6 wherein R6 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; X = aryl, heteroaryl, arylheteroaryl, arylaryl, etc.; n = 0 or 1; R1 and R2 independently = H or alkyl; R3 = alkyl, alkenyl, alkynyl, alkoxy, etc.; R4 and R5 independently = H, OH, alkyl, carboxy, alkoxy, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein-tyrosine phosphatase inhibitors. Thus, e.g., II was prepared via reductive amination of 6-amino-2,2-dimethyl-4H-1,3-benzodioxin-4-one (preparation given) with 4-formylbenzoate and subsequent amidation with 3-cyclopentylpropanoyl chloride, debenzylation, amidation with 4-phenoxybenzylamine and deprotection. I were evaluated for inhibition of PTP, and in particular PTP1B; e.g., II possessed an IC50 value of 1.0 µM in assays against PTP1B. As PTP inhibitors, I should be useful for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic

ovary syndrome (PCOS).

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT